Madrigal’s got more positive data for resmetirom, plus news from Aligos and NorthSea
The American Association for the Study of Liver Diseases is set to hold its annual Liver Meeting this weekend in Boston. This morning, we rounded up some of the late-breaking data shared in advance of the upcoming event.
Madrigal Therapeutics presented more positive data from a Phase III trial of its NASH drug candidate, adding fuel to the company’s plans to win the first-ever approval in the challenging indication.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.